These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10371502)

  • 21. Therapeutic dendritic-cell vaccine for simian AIDS.
    Lu W; Wu X; Lu Y; Guo W; Andrieu JM
    Nat Med; 2003 Jan; 9(1):27-32. PubMed ID: 12496959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
    Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
    J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.
    Ridolfi B; Genovese D; Argentini C; Maggiorella MT; Sernicola L; Buttò S; Titti F; Borsetti A; Ensoli B
    Virus Genes; 2008 Feb; 36(1):105-15. PubMed ID: 18049888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
    James JS
    AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
    Borsetti A; Baroncelli S; Maggiorella MT; Moretti S; Fanales-Belasio E; Sernicola L; Tripiciano A; Macchia I; Michelini Z; Belli R; Farcomeni S; Pavone-Cossut MR; Negri D; Caputo A; Bellino S; Butto S; Titti F; Cafaro A; Ensoli B
    Viral Immunol; 2009 Apr; 22(2):117-24. PubMed ID: 19326998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).
    Cafaro A; Titti F; Fracasso C; Maggiorella MT; Baroncelli S; Caputo A; Goletti D; Borsetti A; Pace M; Fanales-Belasio E; Ridolfi B; Negri DR; Sernicola L; Belli R; Corrias F; Macchia I; Leone P; Michelini Z; ten Haaft P; Buttò S; Verani P; Ensoli B
    Vaccine; 2001 Apr; 19(20-22):2862-77. PubMed ID: 11282197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Tat-based vaccines: from basic science to clinical trials.
    Fanales-Belasio E; Cafaro A; Cara A; Negri DR; Fiorelli V; Butto S; Moretti S; Maggiorella MT; Baroncelli S; Michelini Z; Tripiciano A; Sernicola L; Scoglio A; Borsetti A; Ridolfi B; Bona R; Ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Vardas E; Magnani M; Laguardia E; Caputo A; Titti F; Ensoli B
    DNA Cell Biol; 2002 Sep; 21(9):599-610. PubMed ID: 12396602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
    Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
    DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective immune responses induced by a non-pathogenic simian/human immunodeficiency virus (SHIV) against a challenge of a pathogenic SHIV in monkeys.
    Yoshino N; Ami Y; Someya K; Ando S; Shinohara K; Tashiro F; Lu Y; Honda M
    Microbiol Immunol; 2000; 44(5):363-72. PubMed ID: 10888354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
    Cafaro A; Bellino S; Titti F; Maggiorella MT; Sernicola L; Wiseman RW; Venzon D; Karl JA; O'Connor D; Monini P; Robert-Guroff M; Ensoli B
    J Virol; 2010 Sep; 84(17):8953-8. PubMed ID: 20554774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tat toxoid: its potential role as an HIV vaccine.
    Lambert J
    J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
    [No Abstract]   [Full Text] [Related]  

  • 37. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?
    Sealy R; Zhan X; Lockey TD; Martin L; Blanchard J; Traina-Dorge V; Hurwitz JL
    Curr HIV Res; 2009 Sep; 7(5):497-503. PubMed ID: 19925400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL; Barouch DH; Montefiori DC
    Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
    Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
    Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.